TG Therapeutics, Inc. (TGTX) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated August 2, 2021, serves as a current report for TG Therapeutics, Inc. It references a press release issued on the same date announcing the results of operations for the three and six months ended June 30, 2021. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol TGTX.
Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1), which is furnished but not included in the text of this Form 8-K.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the body text. It directs readers to the attached press release for the comparative analysis of the three and six months ended June 30, 2021.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, risk factors, and contingencies are not detailed in this specific filing. The document states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the specific financial results for the three and six months ended June 30, 2021, by reviewing the press release attached as Exhibit 99.1.
- Confirm the company's cash position and burn rate, as this 8-K does not list liquidity figures.
- Note that the financial data in this filing is not incorporated by reference into other SEC filings unless specifically cited.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the August 2, 2021 press release.